How Gilead Did Trial Diversity Before It Was Cool
Thanks in part to its HIV focus, Gilead was an early adopter when it came to emphasizing diversity in trials.
You may also be interested in...
In this week's podcast edition of Five Must-Know Things: BMS buys Mirati; slow Q3 for biopharma M&A; Roche on its neuroscience strategy; Alexion talks about AstraZeneca integration; and Gilead on trial diversity.
New guidance is due in a few months that should answer questions about how the FDA will react if a sponsor does not reach its clinical trial diversity goals.
Sales of the COVID-19 antiviral continued their long decline, but even when factoring those in, Gilead’s overall revenue increased by 5% year-over-year.